Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children

J Infect. 2011 Oct;63(4):288-94. doi: 10.1016/j.jinf.2011.06.008. Epub 2011 Jun 22.

Abstract

Objective: There were many cases of pandemic influenza A (H1N1) 2009 (H1N1/09) in Japan during the 2009-2010 epidemic. They accounted for 16% of the total population (20.7 million/128 million), and 59% of the patients were children 15 years of age and under (12.2 million/20.7million). However, there were only 38 paediatric deaths. We analyzed the clinical manifestations and treatment of children hospitalized because of H1N1/09 infection in order to clarify the association between treatment with neuraminidase inhibitors and the low mortality rate.

Methods: A retrospective chart review was performed on a total of 1000 paediatric inpatients.

Results: The causes of the hospitalizations were respiratory complications in 651 cases (65.1%), neurological complications in 255 cases (25.5%) and other complications in 94 cases. Neuraminidase inhibitors, primarily oseltamivir, had been used to treat 984 (98.4%) of the 1000 patients, and in 88.9% of the patients, treatment with neuraminidase inhibitors was initiated within 48 h after the onset of illness. Only 12 (1.2%) of the 1000 patients underwent mechanical ventilation, and one patient died of H1N1/09 infection.

Conclusions: Although a high proportion of the patients in this study had severe respiratory complications, the case fatality rate was only 0.1%. The low mortality rate of children due to the H1N1/09 epidemic in Japan was probably attributable to the universal implementation of early treatment with neuraminidase inhibitors.

MeSH terms

  • Adolescent
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology
  • Child
  • Child, Hospitalized
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype / drug effects
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza, Human / drug therapy*
  • Influenza, Human / mortality*
  • Influenza, Human / virology
  • Japan
  • Male
  • Neuraminidase / antagonists & inhibitors
  • Oseltamivir / administration & dosage*
  • Oseltamivir / pharmacology
  • Retrospective Studies
  • Time Factors
  • Viral Proteins / antagonists & inhibitors
  • Young Adult

Substances

  • Antiviral Agents
  • Viral Proteins
  • Oseltamivir
  • NA protein, influenza A virus
  • Neuraminidase